SCHEMBL515623

SCHEMBL515623

CCCCCCCCCCCOCCCC(=O)O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 7/20 0.67
PPARG P37231 7/20 0.67
PPARD Q03181 7/20 0.67
PPARA Q07869 7/20 0.67
HDAC11 Q96DB2 5/20 0.67
TSHR P16473 4/20 0.67
PTPN1 P18031 3/20 0.67
ALDH1A1 P00352 3/20 0.67
KMT2A Q03164 3/20 0.67
TLR2 O60603 2/20 0.67
TDP1 Q9NUW8 2/20 0.67
FABP4 P15090 2/20 0.67
MEN1 O00255 2/20 0.67
SLC22A6 Q4U2R8 1/20 0.67
SLC22A8 Q8TCC7 1/20 0.67
ESR1 P03372 1/20 0.67
ALOX15 P16050 1/20 0.67
PDE4A P27815 1/20 0.67
PDE3A Q14432 1/20 0.67
HSD17B10 Q99714 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7764672 1.00 GPR84 (0.67) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL11228821 1.00 GPR84 (0.67) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL28439052 1.00 GPR84 (0.67) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL9455451 1.00 GPR84 (0.67) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL9503519 1.00 GPR84 (0.67) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL6803390 1.00 GPR84 (0.67) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL7496947 1.00 GPR84 (0.67) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL9065811 1.00 GPR84 (0.67) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL9066363 1.00 GPR84 (0.67) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL17908855 0.98 GPR84 (0.64) GPR84PPARGPPARDPPARAHDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2566494-B1 CXCR4 RECEPTOR COMPOUNDS ACER THERAPEUTICS INC (US) 2017-11-29 EP disclosed
US-20160159861-A1 APJ Receptor Compounds ANCHOR THERAPEUTICS, INC. (US) 2016-06-09 US disclosed
US-20160159861-A1 APJ Receptor Compounds ANCHOR THERAPEUTICS, INC. (US) 2016-06-09 US disclosed
EP-3021861-A1 APJ RECEPTOR COMPOUNDS Anchor Therapeutics, Inc. (US) 2016-05-25 EP disclosed
US-9155795-B2 CXCR4 receptor compounds ANCHOR THERAPEUTICS, INC. (US) 2015-10-13 US disclosed
US-9155795-B2 CXCR4 receptor compounds ANCHOR THERAPEUTICS, INC. (US) 2015-10-13 US disclosed
US-9096646-B2 CXCR4 receptor compounds ANCHOR THERAPEUTICS, INC. (US) 2015-08-04 US disclosed
US-9096646-B2 CXCR4 receptor compounds ANCHOR THERAPEUTICS, INC. (US) 2015-08-04 US disclosed
WO-2015010045-A1 APJ RECEPTOR COMPOUNDS ANCHOR THERAPEUTICS, INC. (US) 2015-01-22 WO disclosed
WO-2015010045-A1 APJ RECEPTOR COMPOUNDS ANCHOR THERAPEUTICS, INC. (US) 2015-01-22 WO disclosed
WO-2010053547-A2 CXCR5 RECEPTOR COMPOUNDS ANCHOR THERAPEUTICS, INC. (US) 2010-05-14 WO disclosed
WO-2010053547-A2 CXCR5 RECEPTOR COMPOUNDS ANCHOR THERAPEUTICS, INC. (US) 2010-05-14 WO disclosed
WO-2010053550-A2 CXCR4 RECEPTOR COMPOUNDS ANCHOR THERAPEUTICS, INC. (US) 2010-05-14 WO disclosed
WO-2010053548-A2 PTHR1 RECEPTOR COMPOUNDS ANCHOR THERAPEUTICS, INC. (US) 2010-05-14 WO disclosed
WO-2010053548-A2 PTHR1 RECEPTOR COMPOUNDS ANCHOR THERAPEUTICS, INC. (US) 2010-05-14 WO disclosed
EP-0396429-B1 Polyurethane-based polymeric materials and biomedical articles and pharmaceutical compositions utilizing the same BIOMEDICAL POLYMERS INT (US) 1996-07-31 EP disclosed
EP-0543865-A1 BENZAMIDE DERIVATIVES RHONE-POULENC RORER LIMITED (GB) 1993-06-02 EP disclosed
US-5100992-A Chain extended with a dicarboxylic acid, block and graft polymers, medical applications, drug delivery BIOMEDICAL POLYMERS INTERNATIONAL, LTD. (US) 1992-03-31 US disclosed
WO-1992003412-A2 BENZAMIDE DERIVATIVES RHONE-POULENC RORER LIMITED (GB) 1992-03-05 WO disclosed
EP-0396429-A2 Polyurethane-based polymeric materials and biomedical articles and pharmaceutical compositions utilizing the same BIOMEDICAL POLYMERS INTERNATIONAL, LTD. (US) 1990-11-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160159861-A1 APJ Receptor Compounds APLNR, AP1G1, AP2B1 GPR84 44/4885PPARG 213/4885PPARD 763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.